Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22-Targeted CAR-T in B Cell Malignancies
NCT02935153Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD22 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences) in B-cell leukemia (BCL), B cell lymphoma, sponsored by Southwest Health System. Status: unknown.
02
Drugs
Anti-CD22 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT02935153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935153.